Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

被引:4
作者
Maserati, R
Cagni, AE
Segu, C
机构
[1] Experimental Infection Laboratory, Infectious Disease Department, IRCCS Policlinico San Matteo, University of Pavia
关键词
sparfloxacin; experimental endocarditis; Staphylococcus aureus; rabbit;
D O I
10.1159/000239432
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sparfloxacin, a new difluorinated quinolone antibiotic, was employed in the treatment of catheter-induced endocarditis in rabbits infected with a methicillin-resistant strain of Staphylococcus aureus (MRSA). Animals (n = 12) in the study group received sparfloxacin, 25 mg/kg body weight every 12 h intravenously. Comparison groups were untreated controls (n = 9) and animals injected with vancomycin (n = 13) at the same dosage. MICs and MBCs of the test organism were both 1.56 mg/l for vancomycin and 0.15/0.30 mg/l for sparfloxacin. Antibiotic treatments started 24 h after bacterial challenge and lasted 4 days until sacrifice. In comparison with no treatment, both sparfloxacin and vancomycin significantly reduced the bacterial counts in aortic vegetations, while no significant difference was found between the two antibiotics. Combination of the two antibiotics, tried in a smaller group of rabbits (n = 3) showed no advantages over either single-drug therapy. Our results suggest that sparfloxacin is a potentially useful agent, at least in the rabbit model, for treating MRSA endocardial infections.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 29 条
[1]  
AUBIER M, 1993, 33 INT C ANT AG CHEM
[2]  
BADDOUR LM, 1989, REV INFECT DIS, V11, P452
[3]  
BLATTER M, 1993, 33 INT C ANT AG CHEM
[4]   ENOXACIN COMPARED WITH CEFOPERAZONE FOR THE TREATMENT OF EXPERIMENTAL ENTEROBACTER-AEROGENES ENDOCARDITIS [J].
BOSCIA, JA ;
KOBASA, WD ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (05) :708-711
[5]   INVITRO ACTIVITY OF SPARFLOXACIN COMPARED WITH THOSE OF 5 OTHER QUINOLONES [J].
CANTON, E ;
PEMAN, J ;
JIMENEZ, MT ;
RAMON, MS ;
GOBERNADO, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :558-565
[6]   ANTISTAPHYLOCOCCAL ACTIVITIES OF SPARFLOXACIN (CI-978-AT-4140), OFLOXACIN, AND CIPROFLOXACIN [J].
CHAUDHRY, AZ ;
KNAPP, CC ;
SIERRAMADERO, J ;
WASHINGTON, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1843-1845
[7]   INVITRO ACTIVITY OF SPARFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL AGENT [J].
COOPER, MA ;
ANDREWS, JM ;
ASHBY, JP ;
MATTHEWS, RS ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :667-676
[8]   ORAL RIFAMPIN PLUS OFLOXACIN FOR TREATMENT OF STAPHYLOCOCCUS-INFECTED ORTHOPEDIC IMPLANTS [J].
DRANCOURT, M ;
STEIN, A ;
ARGENSON, JN ;
ZANNIER, A ;
CURVALE, G ;
RAOULT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1214-1218
[9]  
DWORKIN RJ, 1989, LANCET, V2, P1071
[10]  
FEKETY R, 1990, PRINCIPLES PRACTICE, P317